Dario Unveils Comprehensive GLP-1 Program for Enhanced Chronic Care Management Experience

Dario Unveils a Revolutionary Integrated GLP-1 Program

In an exciting development for chronic care management, DarioHealth Corp. has announced the launch of its Integrated GLP-1 Program. This innovative program merges their digital chronic care platform with clinical care provided by licensed healthcare professionals, resulting in a seamless, comprehensive experience for users. This initiative marks Dario's first commercial product developed in collaboration with Beluga Health, a strategic partner focused on enhancing patient care through technology.

A New Approach to Chronic Condition Management

DarioHealth has a long-standing history of supporting individuals undergoing GLP-1 therapy, offering resources that include AI-powered engagement, connected monitoring tools, and personalized coaching on nutrition and behavioral health. With the launch of the Integrated GLP-1 Program, patients can now access medical evaluations, prescriptions, and ongoing clinical oversight all within the same digital platform they rely on for chronic care management. This integration means that digital and clinical care are no longer isolated functions; they now exist as a unified journey towards improved health outcomes.

Erez Raphael, the CEO of DarioHealth, emphasized the significance of this development: "Dario has expanded beyond just providing engagement and monitoring around prescriptions. With Beluga’s clinical infrastructure incorporated into our platform, we can now offer a full-cycle support system that starts from evaluation to ongoing chronic care management. This represents a transformative shift in our business model and extends our revenue opportunities."

Addressing a Changing Healthcare Landscape

This launch comes at a critical juncture, as employers are increasingly reevaluating their offerings related to GLP-1 therapies. According to a recent report by the Business Group on Health, a notable percentage of employers are shifting from broad coverage to clinically managed models. This trend requires more stringent eligibility verification, which aligns perfectly with Dario’s Integrated GLP-1 Program as it facilitates thorough clinical evaluations.

As evidence of this transition, statistics show that around 67% of surveyed employers planned to cover GLP-1 medications for weight management in 2026. However, only 72% of these employers expected to continue this coverage into 2027, indicating a potential tightening in the market. The growing use of direct-to-consumer platforms is also noteworthy, as 27% of employers encourage employees to access GLP-1 therapies through such avenues.

The Integrated GLP-1 Program is designed to meet this demand, providing a health management solution that is both accessible and clinically rigorous. This approach makes it an appealing option for employers and health plans aiming to maintain high standards for member care while navigating budget constraints.

Multi-Channel Access for Greater Reach

The Integrated GLP-1 Program will be accessible via three primary channels:

1. Direct-to-Consumer: Through Dario's MyDario Shop, which will launch in Fall 2026. Over the past three years, the digital marketplace has successfully catered to more than 1 million consumers, allowing extensive outreach.
2. Health Plan Marketplaces: By positioning the program as a clinically managed option for health plans, Dario provides a sustainable alternative for coverage that ensures proper guidance on prescribing GLP-1 medications.
3. Employer B2B2C Programs: Dario will also integrate this offering as a value-added service for its existing enterprise clients. This extends an economical solution for employers who are conscious of costs associated with obesity treatment through GLP-1 medications.

These access points not only facilitate user engagement but also generate valuable data that the AI engine, DarioIQ™, can utilize to optimize both clinical outcomes and cost savings.

Commitment to Responsible Care

DarioHealth emphasizes that clinical eligibility for GLP-1 therapy will be determined by licensed healthcare providers. This ensures that only those meeting established criteria will receive prescriptions, showcasing Dario’s dedication to responsible, evidence-based care practices.

As an AI-powered healthcare technology leader, DarioHealth continues to transform chronic care management for individuals with various conditions, including diabetes and hypertension. By combining technology with clinical expertise, the Integrated GLP-1 Program is set to not only improve user experience but also address the needs of employers and health plans navigating a shifting healthcare landscape.

In conclusion, DarioHealth’s Integrated GLP-1 Program represents a significant advancement in chronic care management, promising to deliver enhanced health outcomes while navigating the complexities of modern healthcare. With a consumer-centric approach, Dario is poised to make waves in the field of chronic condition management as it rolls out this remarkable offering.